A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

ClinicalTrials.gov ID: NCT02340975

Public ClinicalTrials.gov record NCT02340975. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in participants with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma.

Study identification

NCT ID: NCT02340975
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: MedImmune LLC; Industry
Enrollment: 114 participants

Conditions and interventions

Conditions

Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

MEDI4736 + tremelimumab Biological
MEDI4736 Biological
Tremelimumab Biological

Biological

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2015 (Actual)
Primary completion: Apr 29, 2019 (Actual)
Completion: Apr 29, 2019 (Actual)
Last update posted: Jun 9, 2020

2015 – 2019

United States locations

U.S. sites: 15
U.S. states: 12
U.S. cities: 13

Facility	City	State	ZIP	Site status
Research Site	Los Angeles	California	90033	—
Research Site	Santa Monica	California	90404	—
Research Site	New Haven	Connecticut	06520	—
Research Site	Tampa	Florida	33612	—
Research Site	Chicago	Illinois	60637	—
Research Site	Baltimore	Maryland	21231	—
Research Site	New York	New York	10032	—
Research Site	New York	New York	10065	—
Research Site	New York	New York	10116	—
Research Site	Cleveland	Ohio	44106	—
Research Site	Portland	Oregon	97213	—
Research Site	Philadelphia	Pennsylvania	19111	—
Research Site	Greenville	South Carolina	29605	—
Research Site	Nashville	Tennessee	37203	—
Research Site	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02340975, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 9, 2020 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02340975 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →